- $513.89m
- $417.99m
- $85.23m
Delcath Systems Inc expected to post a loss of 98 cents a share - Earnings Preview
Brief: Delcath Systems Files Prospectus Related To Offer And Resale Of Up To 1.26 Million Shares Of Common Stock Offered By Selling Stockholders - SEC Filing
Delcath Systems Inc reports results for the quarter ended in June - Earnings Summary
Brief: Delcath Systems Reports Q2 Loss Of 96 Cents Per Share
Delcath Systems Inc reports results for the quarter ended in March - Earnings Summary
Brief: Delcath Systems Reports First Quarter 2022 Results And Provides Business Update
Delcath Systems Inc expected to post a loss of 88 cents a share - Earnings Preview
Canaccord Genuity cuts Delcath PT ahead of FDA meet for cancer product
BTIG bullish on Delcath as timeline for cancer product approval appears steady
Delcath Systems Inc reports results for the quarter ended in December - Earnings Summary
Brief: Delcath Systems Reports Fourth Quarter And Full-Year 2021 Results
Delcath Systems Inc expected to post a loss of $1.01 a share - Earnings Preview
Brief: Delcath Systems Achieves Medical Device Regulation Certification for CHEMOSAT in Europe
Brief: Delcath Systems Announces Move To A Direct Sales And Marketing Model For Chemosat
Brief: Results Of Single Center Study On Delcath’s Chemosat Hepatic Delivery System Published In Melanoma Research
Brief: Delcath Systems Inc Says On Dec 30, 2021, Unit Received Letter From Medac Stating That Medac Was Terminating Agreement With Immediate Effect
Brief: Delcath Systems Inc Announces Positive Phase 3 Trial Results For Hepzato™ In Liver-Dominant Metastatic Ocular Melanoma
Delcath Systems rises on positive data on cancer drug
NASDAQ RESUMED AT 08:31 AM